[{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","commit":"d1f1037d6e","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on thirty more companies","file":"src/data/spikes/urothelial.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.ferring.com\" }]"}]},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/urothelial.ts","type":"changed","fields":[{"field":"tldr","before":"\"Private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.\"","after":"\"Ferring is the private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.\""}]},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","commit":"06611b41fb","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: SCLC, mesothelioma, urothelial, RCC deep dives with structured outcomes, dosing, toxicity, regulatory events","file":"src/data/spikes/urothelial.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"kind"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"asOf"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]}]